4.0
2 Feb 2017
Anonymous employee
Current employee
Recommend
CEO approval
Business outlook
Pros
. Great balance between long-term outlook provided by the 70% Merck family ownership and performance discipline provided by the 30% stock float . Exciting vision from new leadership team as a Science and Technology company spanning BioPharmaceuticals, LifeSciences and Performance Materials
Cons
. Some of the systems and processes are not as advanced as other leading Global Pharmaceutical companies (e.g., HR, Finance) . Challenging to change across different divisions in Marketing & Sales . Unclear role for some businesses (e.g. Consumer Health) within new vision